pdf   xlsx method abbreviations

metastatic/advanced UC (mUC) - 1st Line (L1), atezolizumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.92 [0.75, 1.12]< 154%2 studies (2/-)80.1 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.82 [0.70, 0.96]< 10%1 study (1/-)99.3 %NAnot evaluable important-
CRR 1.96 [1.21, 3.17]> 10%1 study (1/-)99.7 %NAnot evaluable non important-
DOR 0.39 [0.12, 1.28]< 191%2 studies (2/-)94.0 %some concernnot evaluable moderatenon important-
objective responses (ORR) 0.67 [0.23, 1.96]> 196%2 studies (2/-)23.1 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE (any grade) 0.52 [0.03, 8.39]< 187%2 studies (2/-)67.6 %some concernnot evaluable moderatenon important-
AE (grade 3-4) 0.33 [0.05, 2.43]< 198%2 studies (2/-)86.0 %some concernnot evaluable moderatenon important-
AE leading to death (grade 5) 1.42 [0.93, 2.15]< 10%2 studies (2/-)5.1 %some concernnot evaluable moderatenon important-
AE leading to treatment discontinuation (any grade) 0.38 [0.05, 2.90]< 198%2 studies (2/-)82.5 %some concernnot evaluable moderatenon important-
SAE (any grade) 0.94 [0.67, 1.32]< 167%2 studies (2/-)64.3 %some concernnot evaluable moderatenon important-
STRAE (any grade) 0.74 [0.23, 2.37]< 196%2 studies (2/-)69.3 %some concernnot evaluable moderatenon important-
TRAE (any grade) 0.26 [0.02, 3.85]< 197%2 studies (2/-)83.3 %some concernnot evaluable moderatenon important-
TRAE (grade 3-4) 0.21 [0.01, 4.65]< 199%2 studies (2/-)83.6 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 1.40 [0.55, 3.56]< 10%2 studies (2/-)23.7 %some concernnot evaluable moderatenon important-

TRAE (grade 3-4) endpoints 00

Anaemia TRAE (grade 3-4) 0.30 [0.02, 4.49]< 192%2 studies (2/-)80.4 %some concernnot evaluable moderatenon important-
Asthenia TRAE (grade 3-4) 1.21 [0.39, 3.76]< 155%2 studies (2/-)36.9 %some concernnot evaluable moderatenon important-
Decreased appetite TRAE (grade 3-4) 2.41 [0.46, 12.52]< 10%2 studies (2/-)14.9 %some concernnot evaluable moderatenon important-
Fatigue TRAE (grade 3-4) 1.61 [0.48, 5.41]< 120%2 studies (2/-)22.0 %some concernnot evaluable moderatenon important-
Nausea TRAE (grade 3-4) 1.11 [0.24, 5.19]< 14%2 studies (2/-)44.8 %some concernnot evaluable moderatenon important-
Neutropenia TRAE (grade 3-4) 0.32 [0.01, 18.35]< 188%2 studies (2/-)70.7 %some concernnot evaluable moderatenon important-
Pruritus TRAE (grade 3-4) 1.42 [0.11, 18.55]< 10%2 studies (2/-)39.5 %some concernnot evaluable moderatenon important-
Rash TRAE (grade 3-4) 2.36 [0.21, 26.86]< 10%2 studies (2/-)24.7 %some concernnot evaluable moderatenon important-
Thrombocytopenia TRAE (grade 3-4) 0.35 [0.03, 4.69]< 183%2 studies (2/-)78.5 %some concernnot evaluable moderatenon important-

AE (grade 3-4) endpoints 00

Anaemia AE (grade 3-4) 0.29 [0.02, 3.86]< 199%2 studies (2/-)82.3 %some concernnot evaluable moderatenon important-
Asthenia AE (grade 3-4) 0.88 [0.32, 2.41]< 178%2 studies (2/-)59.5 %some concernnot evaluable moderatenon important-
Fatigue AE (grade 3-4) 0.41 [0.14, 1.17]< 175%2 studies (2/-)95.2 %some concernnot evaluable moderatenon important-
Febrile neutropenia AE (grade 3-4) 0.41 [0.01, 11.84]< 181%2 studies (2/-)69.7 %some concernnot evaluable moderatenon important-
Hypertension AE (grade 3-4) 1.16 [0.29, 4.59]< 177%2 studies (2/-)41.4 %some concernnot evaluable moderatenon important-
Leucopenia AE (grade 3-4) 0.14 [0.00, 5.94]< 186%2 studies (2/-)84.5 %some concernnot evaluable moderatenon important-
Nausea AE (grade 3-4) 0.26 [0.04, 1.67]< 167%2 studies (2/-)92.2 %some concernnot evaluable moderatenon important-
Neutropenia AE (grade 3-4) 0.08 [0.00, 29.10]< 194%2 studies (2/-)79.0 %some concernnot evaluable moderatenon important-
Thrombocytopenia AE (grade 3-4) 0.14 [0.00, 12.34]< 195%2 studies (2/-)79.8 %some concernnot evaluable moderatenon important-
Vomiting AE (grade 3-4) 0.36 [0.04, 2.88]< 173%2 studies (2/-)83.2 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons